Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock

Immunome, Inc. (NASDAQ:IMNM) CEO Clay Siegall bought 4,729 shares of Immunome stock in a transaction on Tuesday, December 30th. The stock was acquired at an average cost of $21.15 per share, with a total value of $100,018.35. Following the acquisition, the chief executive officer owned 665,254 shares of the company’s stock, valued at $14,070,122.10. This trade represents a 0.72% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Immunome Trading Down 1.9%

Shares of NASDAQ:IMNM traded down $0.42 on Tuesday, reaching $21.18. 1,086,787 shares of the company were exchanged, compared to its average volume of 1,282,883. The company has a 50-day moving average of $18.45 and a 200-day moving average of $13.26. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -7.18 and a beta of 2.17. Immunome, Inc. has a 1-year low of $5.15 and a 1-year high of $25.30.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. As a group, analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on IMNM. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research note on Wednesday, October 8th. Guggenheim upped their target price on Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Wedbush reaffirmed an “outperform” rating and set a $21.00 price target on shares of Immunome in a research note on Friday, November 7th. Evercore ISI increased their price objective on shares of Immunome from $18.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Finally, Leerink Partners set a $40.00 target price on shares of Immunome in a research report on Monday, December 15th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.09.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. MetLife Investment Management LLC grew its holdings in Immunome by 19.1% in the 1st quarter. MetLife Investment Management LLC now owns 42,411 shares of the company’s stock valued at $285,000 after buying an additional 6,792 shares during the period. Tema Etfs LLC acquired a new stake in shares of Immunome in the second quarter worth approximately $1,074,000. Kennedy Capital Management LLC grew its holdings in Immunome by 642.6% in the second quarter. Kennedy Capital Management LLC now owns 109,352 shares of the company’s stock valued at $1,017,000 after purchasing an additional 94,627 shares during the period. Adage Capital Partners GP L.L.C. grew its holdings in Immunome by 55.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 775,000 shares of the company’s stock valued at $5,216,000 after purchasing an additional 275,000 shares during the period. Finally, Intech Investment Management LLC increased its position in Immunome by 17.8% during the second quarter. Intech Investment Management LLC now owns 40,565 shares of the company’s stock worth $377,000 after purchasing an additional 6,141 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.